microorganisms Article Inoculation of the Leishmania infantum HSP70-II Null Mutant Induces Long-Term Protection against L. amazonensis Infection in BALB/c Mice Manuel Soto 1,*, Laura Ramírez 1, José Carlos Solana 1,2 , Emma C. L. Cook 3 , Elena Hernández-García 3 , José María Requena 1 and Salvador Iborra 3,* 1 Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain;
[email protected] (L.R.);
[email protected] (J.C.S.);
[email protected] (J.M.R.) 2 WHO Collaborating Centre for Leishmaniasis, National Centre for Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain 3 Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and 12 de Octubre Health Research Institute (imas12), 28040 Madrid, Spain;
[email protected] (E.C.L.C.);
[email protected] (E.H.-G.) * Correspondence:
[email protected] (M.S.);
[email protected] (S.I.); Tel.: +34-91-196-4647 (M.S.); +34-91-394-7220 (S.I.) Abstract: Leishmania amazonensis parasites are etiological agents of cutaneous leishmaniasis in the New World. BALB/c mice are highly susceptible to L. amazonensis challenge due to their inability to mount parasite-dependent IFN-γ-mediated responses. Here, we analyzed the capacity of a single Citation: Soto, M.; Ramírez, L.; administration of the LiDHSP70-II genetically-modified attenuated L. infantum line in preventing Solana, J.C.; Cook, E.C.L.; Hernández- cutaneous leishmaniasis in mice challenged with L. amazonensis virulent parasites. In previous studies, García, E.; Requena, J.M.; Iborra, S.